Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study

Journal of Clinical Psychopharmacology

Volumn 18, Issue 6, 1998, Pages 441-446

  Zanardi, Raffaella ^a   Franchini, Linda ^a   Gasperini, Mariangela ^a   Lucca, Adelio ^a   Smeraldi, Enrico ^a   Perez, Jorge ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; PINDOLOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; MALE; MANIC DEPRESSIVE PSYCHOSIS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUVOXAMINE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; PINDOLOL; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 0031762412     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199812000-00004     Document Type: Article

References (40)

1. Charney DS, Nelson JC. Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. Am J Psychiatry 1981;3:328-33.
2. Parker G, Roy K, Hadzi-Pavlovic D, Pedic F. Psychotic (delusional) depression: a meta-analysis of physical treatments. J Affect Disord 1992;24:17-24.
3. Rothschild AJ. Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am 1996;19:237-52.
4. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 1993;54: 338-42.
5. Wolfersdorf M, Barg T, Konig F, Leibfarth M, Grunewald I. Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychiatry 1995;28:56-60.
6. Bellini L, Gasperini M, Gatti F, Franchini L, Smeraldi E. A double-blind study with fluvoxamine versus desipramine combined with placebo or haloperidol in delusional depression. In: Langer SZ, Brunello N, Racagni G, Mendlewicz J, eds. Critical issues in the treatment of affective disorders: International Academy for Biomedical and Drug Research. Basel, Switzerland: Karger Press, 1994:32-6.
7. Gatti F, Bellini L, Gasperini M, Perez J, Zanardi R, Smeraldi E. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 1996;153:414-6.
8. Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 1996;153: 1631-3.
9. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15:220-5.
10. 1A antagonists. Trends Neurosci 1996;19:378-83.
11. Artigas F. 5-HT and antidepressants: new views from microdialysis studies [letter]. Trends Pharmacol Sci 1993;14:262.
12. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-51.
13. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995;15:217-22.
14. Tome MB, Isaac MT, Harte R, Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997;12:81-9.
15. Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomised, double-blind placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349: 1594-7.
16. Zanardi R, Artigas F, Franchini L, Sforzini L, Gasperini M, Smeraldi E, Perez J. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol 1997;17:446-50.
17. Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-III-R. New York: Biometrics Research Department, New York State Psychiatric Institute, 1985.
18. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
19. Kendler KS, Glazer WM, Morgenstern H. Dimension of delusional experience. Am J Psychiatry 1983;140:466-9.
20. Levin J, Guy W, eds. ECDEU assessment manual. Rockville, MD: Department of Education and Welfare, National Institute of Mental Health Research, 1976.
21. Pullen RH, Fatmi AA. Determination of fluvoxamine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1992;574:101-7.
22. Lucca A, Lucini V, Catalano M, Alfano M, Smeraldi E. Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor. Neuropsychobiology 1994;29:108-11.
23. Cox DR. Regression models and life-tables. J R Stat Soc 1981; 34:187-220.
24. Faul F, Erdfelder E. A priori, post hoc and compromise power analyses for MS-DOS [computer program]. Germany: Bonn University, 1993.
25. Berman RM, Darnell AM, Miller HL, Anand A, Charney DS. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 1997;154:37-43.
26. Dreshfield LJ, Wong DT, Perry KW, Engleman EA. Enhancement of fluoxetine-dependent increase of extracellular serotonin (5-HT) levels by (-)-pindolol, an antagonist at 5-HT1A receptors. Neurochem Res 1996;21:557-62.
27. Bel N, Artigas F. Fluvoxamine preferentially increases extracellular 5- hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 1992;229:101-3.
28. Bel N, Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993;15:243-5.
29. Bosker FJ, Klompmakers AA, Westenberg GM. Effects of single and repeated oral administration of fluvoxamine on extracellular serotonin in the median raphe nucleus and dorsal hippocampus of the rat. Neuropharmacology 1995;34:501-8.
30. 1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci Lett 1996;219:123-6.
31. Howland RH. Biochemical effects of antidepressant augmentation [letter]. Arch Gen Psychiatry 1995;52:156.
32. Artigas F. Pindolol, 5-hydroxytryptamine, and antidepressant augmentation. Arch Gen Psychiatry 1995;52:969-71.
33. Hjorth S, Bengtsson HJ, Milano S. Raphe 5-HT1A autoreceptors, but not postsynaptic 5-HT1A receptors or beta-adrenoreceptors, restrain the citalopram-induced increase in extracellular 5- hydroxytryptamine in vivo. Eur J Pharmacol 1996;316:43-7.
34. Bruinvels AT, Lery H, Nozulak J, Palacios JM, Hoyer D. 5-HT1D binding sites in various species: similar pharmacological profile in dog, monkey, calf, guinea-pig and human brain membranes. Naunyn Schmiedebergs Arch Pharmacol 1992;346:243-8.
35. 1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 1996;15:349-60.
36. Sacchetti E, Conte G, Guarneri L, Calzeroni A, Bertini M, Panariello A. Effectiveness of fluvoxamine and paroxetine in major depressives with psychotic features. Hum Psychopharmacol 1997;12:277-8.
37. Glassman AH, Roose SP. Delusional depression. A distinct clinical entity? Arch Gen Psychiatry 1981;38:424-7.
38. Spiker DG, Kupfer DJ. Placebo response rates in psychotic and nonpsychotic depression. J Affect Disord 1988;14:21-3.
39. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-76.
40. Schatzberg AF, Rothschild AJ, Langlais PJ, Bird ED, Cole JO. A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 1985;19:57-64.